TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26849260

Group type: EXPERIMENTAL
Intervention: WM (education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WM+ (education plus counseling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational control group
Number of subjects: 0
Study: 25670206

Group type: EXPERIMENTAL
Intervention: Quit with PN intervention
Number of subjects: 2390

Group type: EXPERIMENTAL
Intervention: Quitline referral
Number of subjects: 2390

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 2390
Study: 24119735

Group type: EXPERIMENTAL
Intervention: Entecavir antiviral treatment (group A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Natural resolution (group B)
Number of subjects: 61
Study: 20395618

Group type: EXPERIMENTAL
Intervention: donepezil 5 mg/d
Number of subjects: 974

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 974
Study: 19288903

Group type: EXPERIMENTAL
Intervention: Acupuncture (encircling acupuncture around affected focus, common acupuncture at Hegu (LI 4), Xuehai (SP 10), Fenglong (ST 40), Sanyinjiao (SP 6), venesection and cupping twice a week)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isotretinoin Capsules (10 mg, t.i.d.)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (acupuncture and Western medicine)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 52
Study: 17286116

Group type: EXPERIMENTAL
Intervention: Gollin test with incomplete figures and invisible masks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Gollin test with increasing spectral similarity between figure and invisible mask
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Familiar figure or mask parameters
Number of subjects: 73
Study: 12780424

Group type: EXPERIMENTAL
Intervention: Advice plus iron supplement (60 mg Fe2+ or 3.6 mg heme iron plus 24 mg Fe2+)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Advice plus iron supplement (3.6 mg heme iron plus 24 mg Fe2+)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 326
Study: 10798581

Group type: COMPARATOR
Intervention: B mixture (nutritionally balanced amino acid mixture)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Phe/Tyr-free mixture (phenylalanine/tyrosine deficient mixture)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trp-free mixture (mixture deficient in tryptophan)
Number of subjects: 39
Study: 8879982

Group type: EXPERIMENTAL
Intervention: 100 mg of standardized ginseng extract Ginsana G 115
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 1995766

Group type: EXPERIMENTAL
Intervention: High-level IgG substitution (6 g l-1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-level IgG substitution (3 g l-1)
Number of subjects: 8
Study: 6830569

Group type: EXPERIMENTAL
Intervention: Paradoxical Intention (PI)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Self-Statement Training (SST)
Number of subjects: 26
Study: 30239822

Group type: EXPERIMENTAL
Intervention: Photo-elicitation via a private Facebook group co-facilitated by a moderator and a patient-investigator who lives with chronic pain.
Number of subjects: 0
Study: 29362212

Group type: EXPERIMENTAL
Intervention: Experts using high amounts of medical technical jargon (MTJ) in professional forums
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Experts using low amounts of medical technical jargon (MTJ) in advisory forums
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Experts using high amounts of medical technical jargon (MTJ) in advisory forums
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Experts in professional forums
Number of subjects: 98
Study: 26519646

Group type: EXPERIMENTAL
Intervention: Injectable contraceptives
Number of subjects: 2830

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 2830

Group type: COMPARATOR
Intervention: Nonhormonal contraceptive method
Number of subjects: 2830
Study: 24661167

Group type: EXPERIMENTAL
Intervention: Alcohol (0.80 g/kg ETOH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonalcoholic control beverage
Number of subjects: 0
Study: 22159148

Group type: EXPERIMENTAL
Intervention: Acute EPO administration (30,000 IU/d for 3 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chronic EPO administration (5000 IU/week for 13 weeks)
Number of subjects: 16
Study: 20670234

Group type: EXPERIMENTAL
Intervention: mivacurium 0.25 mg.kg(‐1) (Group Miva)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NaCl 0.9% 0.12 ml.kg(‐1) (Group Control)
Number of subjects: 40
Study: 17515023

Group type: EXPERIMENTAL
Intervention: Acupuncture as an adjunct therapy for IVF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 0
Study: 15468545

Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring with uncomplicated anesthetic management
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring with complicated adequate ventilation
Number of subjects: 375
Study: 12124561

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWHs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral anticoagulants (OAs)
Number of subjects: 0
Study: 9656866

Group type: EXPERIMENTAL
Intervention: Irreversible hydrocolloid (alginate) impressions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Condensation silicone impressions
Number of subjects: 0
Study: 7635996

Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous bolus dose of triazolam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.25 mg oral doses of triazolam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.20 mg oral dose of triazolam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5 mg oral dose of triazolam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.4 mg oral doses of triazolam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2677257

Group type: EXPERIMENTAL
Intervention: Lonidamine plus WBRT
Number of subjects: 58

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lonidamine
Number of subjects: 58
Study: 71604

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine during the first 6 postoperative days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (consecutively treated)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Post-lignocaine cessation (7th to 14th postoperative days)
Number of subjects: 42
Study: 29399993

Group type: EXPERIMENTAL
Intervention: in silico null mutations
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: antigen-negative mutations
Number of subjects: 231
Study: 28899522

Group type: EXPERIMENTAL
Intervention: Actigraphy with default settings
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Customized actigraphy settings (10 consecutive immobile minutes for sleep onset or end and an activity threshold of 10)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 50
Study: 25706652

Group type: EXPERIMENTAL
Intervention: Routine viral load (VL) monitoring
Number of subjects: 820

Group type: COMPARATOR
Intervention: Standard of care (clinical and immunological monitoring)
Number of subjects: 820
Study: 23803700

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21084254

Group type: COMPARATOR
Intervention: Bone turnover markers (OC, BALP, CTX) before treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bone turnover markers during chemotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bone turnover markers after therapy
Number of subjects: 55
Study: 19032727

Group type: EXPERIMENTAL
Intervention: 5 mg kg(‐1) dexibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7 mg kg(‐1) dexibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg kg(‐1) ibuprofen
Number of subjects: 0
Study: 15736460

Group type: EXPERIMENTAL
Intervention: Conscious sedation without opiates
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conscious sedation with opiates
Number of subjects: 400
Study: 12495164

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by a pharmacist‐managed hypertension clinic
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care from their physicians
Number of subjects: 56
Study: 9803103

Group type: EXPERIMENTAL
Intervention: 21 G needle
Number of subjects: 125

Group type: COMPARATOR
Intervention: 23 G needle
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Comparison of 21 G and 23 G needles
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 21 G needle and 23 G needle
Number of subjects: 125
Study: 8572624

Group type: EXPERIMENTAL
Intervention: Adjuvant perioperative portal liver infusion with fluorouracil, mitomycin and heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant subclavian intravenous infusion with fluorouracil, mitomycin and heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No adjuvant treatment (Control group)
Number of subjects: 0
Study: 2510054

Group type: EXPERIMENTAL
Intervention: Cefazedone (single-dose prophylactic administration)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 50
Study: 794717

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 883
Study: 31554943

Group type: EXPERIMENTAL
Intervention: Conbercept (0.2 ml)
Number of subjects: 96

Group type: COMPARATOR
Intervention: 5‐fluorouracil (0.2 ml)
Number of subjects: 96
Study: 30760161

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28566087

Group type: EXPERIMENTAL
Intervention: Emergency access button
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal telephone waiting line
Number of subjects: 0
Study: 24916013

Group type: EXPERIMENTAL
Intervention: Vitamin C plus B vitamins (400 µg folic acid, 2 mg B6, and 10 µg B12)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Vitamin C (50 mg; control group)
Number of subjects: 390
Study: 23643564

Group type: EXPERIMENTAL
Intervention: Emotional and cigarette-related pictures
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High-arousing erotic and mutilation pictures
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-arousing pleasant and unpleasant objects
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cigarette stimuli containing people versus objects
Number of subjects: 180

Group type: COMPARATOR
Intervention: Smokers versus never-smokers (N=40)
Number of subjects: 180
Study: 21666543

Group type: EXPERIMENTAL
Intervention: Borg's Rating of Perceived Exertion (RPE) scale after managing a simulated critical incident
Number of subjects: 17

Group type: COMPARATOR
Intervention: Borg's Rating of Perceived Exertion (RPE) scale during normal anaesthesia induction
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Reliability of the RPE scale for uneventful sessions
Number of subjects: 17
Study: 19635338

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TSE
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 17109336

Group type: EXPERIMENTAL
Intervention: Study vaccine at 2 mg (n=5)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Study vaccine at 4 mg (n=20)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Study vaccine at 8 mg (n=15)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 50
Study: 15236274

Group type: EXPERIMENTAL
Intervention: Mercaptopurine 75 mg/m2 daily
Number of subjects: 226

Group type: COMPARATOR
Intervention: Mercaptopurine 37.5 mg/m2 twice daily
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Comparison of daily vs twice daily dosing
Number of subjects: 226
Study: 12174398

Group type: EXPERIMENTAL
Intervention: Community-based health promotion interventions; specific details on dosage and duration not available.
Number of subjects: 0
Study: 9401427

Group type: COMPARATOR
Intervention: 200 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of 200 mg caffeine and a short nap
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8185426

Group type: EXPERIMENTAL
Intervention: Hydralazine hydrochloride‐isosorbide dinitrate combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (digoxin and diuretic therapy)
Number of subjects: 0
Study: 3583499

Group type: EXPERIMENTAL
Intervention: Atropine infusion with Method A
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atropine infusion with Method B
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 6
Study: 29770466

Group type: EXPERIMENTAL
Intervention: Withania somnifera
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intergroup comparison
Number of subjects: 100
Study: 27524103

Group type: COMPARATOR
Intervention: Long schedule (3 months for hip or 6 months for knee prostheses)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Short schedule (8 weeks)
Number of subjects: 63
Study: 24709463

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF) 100 mg/day
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF) 100 mg/day + Lactobacillus rhamnosus GG (LGG) 6×10(9) CFU/day
Number of subjects: 743

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 743
Study: 24173546

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intercostal nerve block (ICNB) with 0.5% bupivacaine and 1/200,000 epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (sham block)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intercostal nerve block (ICNB)
Number of subjects: 40
Study: 20691707

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2, 10(‐6) to 10(‐9)M)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE, 10(‐5) to 10(‐7)M)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: TIVI vs LDF
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Correlation between TIVI and LDF
Number of subjects: 7
Study: 19043378

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (2 mg x kg(‐1) x h(‐1); group A; n=27)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.9% saline as placebo (group B; n=27)
Number of subjects: 54
Study: 15530134

Group type: EXPERIMENTAL
Intervention: ER-tolterodine with antacid
Number of subjects: 0

Group type: COMPARATOR
Intervention: ER-tolterodine without antacid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ER-oxybutynin with antacid
Number of subjects: 0

Group type: COMPARATOR
Intervention: ER-oxybutynin without antacid
Number of subjects: 0
Study: 11676100

Group type: EXPERIMENTAL
Intervention: Attention to car ads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention to skin-care ads
Number of subjects: 0
Study: 9558750

Group type: EXPERIMENTAL
Intervention: Diet supplemented with n-3 PUFA
Number of subjects: 0
Study: 7934985

Group type: EXPERIMENTAL
Intervention: Glucose alone (GLUC) 4.1 mg/kg/min, n = 8
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glucose with amino acids (TPN) 275 mg N/kg/d, n = 10
Number of subjects: 18
Study: 3300045

Group type: EXPERIMENTAL
Intervention: Trimethoprim (2 X 200 mg for 10 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cotrimoxazole (2 X 160 mg Trimethoprim + 800 mg Sulphamethoxazole for 10 days)
Number of subjects: 40
Study: 31310991

Group type: EXPERIMENTAL
Intervention: Individual counseling and referral for physical activity programs group (CRG)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Minimal intervention group
Number of subjects: 142

Group type: COMPARATOR
Intervention: Physician-based counseling group
Number of subjects: 142
Study: 30098861

Group type: EXPERIMENTAL
Intervention: Inhaled milrinone (50 µg/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inhaled levosimendan (24 µg/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 150
Study: 26563405

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme in addition to high-dose methylprednisolone (HDMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid therapy alone (HDMP)
Number of subjects: 0
Study: 24326731

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (heart-rate reserve 40-60%) for 8 weeks
Number of subjects: 77
Study: 23149528

Group type: EXPERIMENTAL
Intervention: Contraceptive vital sign intervention (n = 26)
Number of subjects: 2304

Group type: COMPARATOR
Intervention: Control group (n = 27)
Number of subjects: 2304
Study: 20843662

Group type: EXPERIMENTAL
Intervention: Waon therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (conventional therapy)
Number of subjects: 21
Study: 17944896

Group type: EXPERIMENTAL
Intervention: Morning bright light
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Evening bright light
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All-day bright light
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Standard light
Number of subjects: 66
Study: 16357191

Group type: EXPERIMENTAL
Intervention: Very well done meat consumption (>10 g/d)
Number of subjects: 29361

Group type: EXPERIMENTAL
Intervention: Highest quintile of PhIP intake
Number of subjects: 29361
Study: 11241462

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) given in different three-dose schedules
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) given at 18 months
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group immunized with the current schedule (first dose at 6 months)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Maternal antibodies present at the time of the first dose
Number of subjects: 5
Study: 9215242

Group type: EXPERIMENTAL
Intervention: 5 gm MSG
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 7966058

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 2960474

Group type: EXPERIMENTAL
Intervention: Histamine (6.5 X 10(‐5)‐6.5 X 10(‐3)M)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 31133144

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (250 mg twice daily) with topical 3% tranexamic acid (twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral tranexamic acid (250 mg twice daily) with topical 20% azelaic acid (daily)
Number of subjects: 100
Study: 28096239

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC) for 90 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incubator care (control)
Number of subjects: 40
Study: 26075935

Group type: EXPERIMENTAL
Intervention: HBM-based education for 3 months
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Traditional (didactic) method
Number of subjects: 166

Group type: COMPARATOR
Intervention: No education (control group)
Number of subjects: 166
Study: 22738415

Group type: EXPERIMENTAL
Intervention: Lay-facilitated angina management programme
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study: 21868616

Group type: EXPERIMENTAL
Intervention: Uric acid levels (measured in mg/dl)
Number of subjects: 5827

Group type: COMPARATOR
Intervention: Uric acid ≤8.2 mg/dl
Number of subjects: 5827
Study: 19938160

Group type: EXPERIMENTAL
Intervention: CC genotype
Number of subjects: 250
Study: 16998619

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 15297582

Group type: EXPERIMENTAL
Intervention: Tris-acryl gelatin microspheres
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyvinyl alcohol (PVA) particles
Number of subjects: 100
Study: 11115705

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV + Hib
Number of subjects: 320

Group type: COMPARATOR
Intervention: DTPw-IPV/Hib + HBV
Number of subjects: 320
Study: 9437182

Group type: EXPERIMENTAL
Intervention: Methacholine (MCh: 0.1, 0.8, and 4.0 micrograms/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP: 0.5, 2.5, and 10 micrograms/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (NC)
Number of subjects: 20
Study: 8101194

Group type: EXPERIMENTAL
Intervention: Terazosin (5 mg once daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31128381

Group type: COMPARATOR
Intervention: EPC (Enhanced Primary Care)
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: EPC+C (Enhanced Primary Care plus Individualized Coaching)
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: EPC and EPC+C
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: EPC+C
Number of subjects: 638
Study: 29799827

Group type: EXPERIMENTAL
Intervention: HARDL (HA gel with lidocaine)
Number of subjects: 162

Group type: COMPARATOR
Intervention: HAJUP (HA gel without lidocaine)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: HARDL
Number of subjects: 162

Group type: COMPARATOR
Intervention: HAJUP
Number of subjects: 162
Study: 27115157

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (6 g/day for 8 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Medium-chain triglycerides (MCT) oil (6 g/day for 8 weeks)
Number of subjects: 34
Study: 25273342

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 494
Study: 22447880

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMCs) transendocardial injection (100 million BMCs)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92